12.62
0.55%
-0.07
After Hours:
12.62
Cabaletta Bio Inc stock is currently priced at $12.62, with a 24-hour trading volume of 674.06K.
It has seen a -0.55% decreased in the last 24 hours and a -22.53% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $12.53 pivot point. If it approaches the $13.28 resistance level, significant changes may occur.
Previous Close:
$12.69
Open:
$12.52
24h Volume:
674.06K
Market Cap:
$609.25M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-7.2948
EPS:
-1.73
Net Cash Flow:
$-54.24M
1W Performance:
+3.27%
1M Performance:
-22.53%
6M Performance:
-27.64%
1Y Performance:
-4.10%
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
267 759 3100
Address
2929 Arch Street, Suite 600, Philadelphia, PA
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-05-23 | Initiated | Citigroup | Buy |
Jul-18-23 | Initiated | Guggenheim | Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jun-30-21 | Initiated | Mizuho | Buy |
Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
Oct-13-20 | Initiated | H.C. Wainwright | Buy |
Nov-19-19 | Initiated | Cowen | Outperform |
Nov-19-19 | Initiated | Evercore ISI | Outperform |
Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio's (CABA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
MarketBeat
Cabaletta Bio Inc: Rising -51.84% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
The InvestChronicle
Cabaletta Bio Reports Promising Advances in Autoimmune Disease Trials, Looks to Future Innovations - MyChesCo
MyChesCo
First Turn Management LLC Makes New $3.98 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
MarketBeat
Cabaletta Bio (NASDAQ:CABA) Shares Gap Up to $11.23 - MarketBeat
MarketBeat
Cabaletta Bio to Present at H.C. Wainwright BioConnect Investor Conference - MSN
MSN
Cabaletta Bio Inc Stock (CABA) Financials Data
Cabaletta Bio Inc (CABA) Net Income 2024
CABA net income (TTM) was -$67.67 million for the quarter ending December 31, 2023, a -27.75% decrease year-over-year.
Cabaletta Bio Inc (CABA) Cash Flow 2024
CABA recorded a free cash flow (TTM) of -$54.24 million for the quarter ending December 31, 2023, a -11.06% decrease year-over-year.
Cabaletta Bio Inc (CABA) Earnings per Share 2024
CABA earnings per share (TTM) was -$1.66 for the quarter ending December 31, 2023, a +8.29% growth year-over-year.
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cap:
|
Volume (24h):